Synapse - Works

Results (2639)

Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed / refractory Waldenström macroglobulinemia: Results from the phase 1/2 BRUIN study

Meeting Abstract

Palomba, M. L.; Patel, M. R.; Eyre, T. A.; Jurczak, W.; Lewis, D. J.; Gastinne, T.; Ma, S.; Cohen, J. B.; Patel, K.; Brown, J. R.; more...
Blood (2022)

Fulltext@MSK | Save

Safety and efficacy of the PI3Kδ inhibitor zandelisib in combination with the BTK inhibitor zanubrutinib in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or mantle cell lymphoma (MCL)

Meeting Abstract

Soumerai, J. D.; Diefenbach, C. S.; Samaniego, F.; Kumar, A.; Tsai, M. L.; Asch, A. S.; Jagadeesh, D.; Kenkre, V. P.; Lossos, I. S.; Salman, H.; more...
Blood (2022)

Fulltext@MSK | Save

Tafasitamab and lenalidomide in relapsed/refractory large B cell lymphoma (R/R LBCL): Real world outcomes in a multicenter retrospective study

Meeting Abstract

Qualls, D.; Buege, M. J.; Dao, P.; Caimi, P. F.; Rutherford, S. C.; Wehmeyer, G.; Romancik, J. T.; Leslie, L. A.; Merrill, M. H.; Crombie, J. L.; more...
Blood (2022)

Fulltext@MSK | Save

A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma

Meeting Abstract

Park, J. H.; Palomba, M. L.; Rivière, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
Blood (2022)

Fulltext@MSK | Save

Inflammatory biomarker clusters are predictive of response and toxicity in large B-cell lymphoma treated with CD19 CAR-T cell therapy

Meeting Abstract

Raj, S.; Perales, M. A.; Fein, J. A.; Tomas, A. A.; Batlevi, C. L.; De Lapuerta, M. C.; Dahi, P. B.; Danylesko, I.; Fried, S.; Funnell, T.; more...
Blood (2022)

Fulltext@MSK | Save

Sequencing novel agents in frontline and second-line treatment of Hodgkin lymphoma

Meeting Abstract

Moskowitz, A. J.
Clinical Lymphoma, Myeloma and Leukemia (2022)

Fulltext@MSK | Save

The potential for technology to aid quantitative assessment in cutaneous T cell lymphoma

Correspondence

Gu, L.; Oh, Y.; Smith, M. P.; Kurtansky, N. R.; Horwitz, S.; Kahn, N.; Moskowitz, A.; Noor, S. J.; Myskowski, P.; Rotemberg, V.
Leukemia and Lymphoma (2022)

Fulltext@MSK | Save

Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL)

Meeting Abstract

Wang, M.; Jurczak, W.; Jerkeman, M.; Trotman, J.; Zinzani, P. L.; Walewski, J. A.; Zhu, J.; Spurgeon, S.; Goy, A.; Hamlin, P. A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP ) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study

Meeting Abstract

Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J.; Herbaux, C.; Burke, J. M.; Matasar, M.; more...
Oncology Research and Treatment (2022)

Fulltext@MSK | Save

VITALIZE: A phase IIb, open-label, multicenter, randomized parallel-group, two-stage, study of maveropepimut-S, pembrolizumab, with or without intermittent low-dose cyclophosphamide, in r/r DLBCL

Meeting Abstract

Matasar, M.; Teti, J.; Mody, K.; Fiset, S.; Graff, J.
Annals of Oncology (2022)

Fulltext@MSK | Save